News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
728,977 Results
Type
Article (44596)
Company Profile (310)
Press Release (684071)
Multimedia
Podcasts (94)
Webinars (12)
Section
Business (212950)
Career Advice (2191)
Deals (37148)
Drug Delivery (115)
Drug Development (84394)
Employer Resources (177)
FDA (16806)
Job Trends (15617)
News (361135)
Policy (34905)
Tag
Academia (2650)
Accelerated approval (5)
Adcomms (26)
Allergies (91)
Alliances (52228)
ALS (96)
Alzheimer's disease (1415)
Antibody-drug conjugate (ADC) (143)
Approvals (16795)
Artificial intelligence (278)
Autoimmune disease (26)
Automation (16)
Bankruptcy (377)
Best Places to Work (11865)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (194)
Bladder cancer (80)
Brain cancer (29)
Breast cancer (286)
Cancer (2350)
Cardiovascular disease (192)
Career advice (1827)
Career pathing (33)
CAR-T (159)
Cell therapy (443)
Cervical cancer (20)
Clinical research (68601)
Collaboration (879)
Company closure (1)
Compensation (548)
Complete response letters (29)
COVID-19 (2701)
CRISPR (46)
C-suite (252)
Cystic fibrosis (103)
Data (2238)
Decentralized trials (2)
Denatured (29)
Depression (48)
Diabetes (287)
Diagnostics (6502)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (125)
Drug pricing (121)
Drug shortages (31)
Duchenne muscular dystrophy (97)
Earnings (89037)
Editorial (41)
Employer branding (21)
Employer resources (152)
Events (116987)
Executive appointments (746)
FDA (18099)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (773)
Gene editing (114)
Generative AI (24)
Gene therapy (327)
GLP-1 (800)
Government (4848)
Grass and pollen (5)
Guidances (67)
Healthcare (19281)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (134)
Indications (30)
Infectious disease (2854)
Inflammatory bowel disease (144)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (342)
IPO (16980)
IRA (48)
Job creations (4173)
Job search strategy (1562)
Kidney cancer (11)
Labor market (38)
Layoffs (511)
Leadership (23)
Legal (8575)
Liver cancer (77)
Lung cancer (332)
Lymphoma (158)
Machine learning (7)
Management (61)
Manufacturing (331)
MASH (72)
Medical device (13572)
Medtech (13577)
Mergers & acquisitions (20718)
Metabolic disorders (760)
Multiple sclerosis (85)
NASH (20)
Neurodegenerative disease (100)
Neuropsychiatric disorders (33)
Neuroscience (1992)
NextGen: Class of 2025 (6744)
Non-profit (4597)
Now hiring (39)
Obesity (411)
Opinion (249)
Ovarian cancer (77)
Pain (98)
Pancreatic cancer (84)
Parkinson's disease (157)
Partnered (21)
Patents (244)
Patient recruitment (113)
Peanut (50)
People (59969)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21366)
Phase II (30124)
Phase III (22592)
Pipeline (1233)
Policy (162)
Postmarket research (2694)
Preclinical (9038)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (256)
Rare diseases (408)
Real estate (6388)
Recruiting (67)
Regulatory (23693)
Reports (46)
Research institute (2405)
Resumes & cover letters (370)
Rett syndrome (5)
RNA editing (5)
RSV (48)
Schizophrenia (78)
Series A (134)
Series B (87)
Service/supplier (15)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (30)
Startups (3799)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (46)
The Weekly (63)
Vaccines (733)
Venture capitalists (41)
Weight loss (291)
Women's health (36)
Worklife (17)
Date
Today (4)
Last 7 days (912)
Last 30 days (2599)
Last 365 days (33574)
2025 (11097)
2024 (36209)
2023 (40991)
2022 (52193)
2021 (56803)
2020 (55308)
2019 (48134)
2018 (36366)
2017 (33657)
2016 (33312)
2015 (39138)
2014 (33077)
2013 (28193)
2012 (30274)
2011 (30960)
2010 (29003)
Location
Africa (820)
Alabama (53)
Alaska (7)
Arizona (242)
Arkansas (14)
Asia (41828)
Australia (6658)
California (6200)
Canada (2047)
China (551)
Colorado (270)
Connecticut (276)
Delaware (153)
Europe (89821)
Florida (930)
Georgia (206)
Idaho (58)
Illinois (556)
India (27)
Indiana (323)
Iowa (11)
Japan (168)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (916)
Massachusetts (4660)
Michigan (222)
Minnesota (396)
Mississippi (2)
Missouri (85)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (64)
New Jersey (1760)
New Mexico (31)
New York (1761)
North Carolina (1024)
North Dakota (8)
Northern California (2701)
Ohio (207)
Oklahoma (14)
Oregon (40)
Pennsylvania (1393)
Puerto Rico (13)
Rhode Island (33)
South America (1190)
South Carolina (23)
South Dakota (1)
Southern California (2320)
Tennessee (102)
Texas (923)
United States (23564)
Utah (184)
Virginia (156)
Washington D.C. (63)
Washington State (564)
West Virginia (3)
Wisconsin (57)
728,977 Results for "astellas pharma canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Press Releases
LSL PHARMA GROUP ANNOUNCES THE SIGNING OF TWO AGREEMENTS TO MARKET NEW OPHTHALMIC PRODUCTS IN CANADA
April 3, 2025
·
1 min read
Press Releases
Astellas Receives Health Canada Approval for VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
January 9, 2025
·
14 min read
BioMidwest
Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery
Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.
April 9, 2024
·
1 min read
Press Releases
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
April 10, 2025
·
7 min read
Business
Vivtex Enters Research Collaboration with Astellas Pharma
Vivtex Corporation announces that it has entered a research collaboration with Astellas Pharma Inc. (“Astellas”), a global pharmaceutical company.
January 23, 2024
·
2 min read
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Press Releases
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada
April 16, 2025
·
8 min read
Press Releases
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
April 9, 2025
·
5 min read
1 of 72,898
Next
